Association of hypoglycemic agents with the risk of platinum-based chemotherapy-induced peripheral neuropathy in patients with type 2 diabetes mellitus
Abstract
Abstract In patients with cancer who also have type 2 diabetes, platinum-based chemotherapy can worsen the neuropathy owing to its neurotoxic effects. Novel glucose-lowering agents may mitigate chemotherapy-induced peripheral neuropathy by improving glycemic control and reducing metabolic stress. However, their clinical utility in reducing the risk of chemotherapy-induced peripheral neuropathy has not been fully validated, and which specific glucose-lowering drugs are associated with a decreased incidence of neuropathy in this context remains unclear. In this retrospective cohort study, we included 119,061 patients with type 2 diabetes who received platinum-based chemotherapy, with data captured from April 2008 to December 2022 in Japan’s Medical Data Vision database We examined their diagnoses, treatments, and procedures, categorizing them into patients with chemotherapy-induced peripheral neuropathy-potentially (n = 22,559) and those without (n = 96,502). The incidence of chemotherapy-induced peripheral neuropathy-potentially was 18.9%. The concomitant use of sodium–glucose cotransporter 2 inhibitors was associated with a significantly lower risk of chemotherapy-induced peripheral neuropathy-potentially, with an overall hazard ratio of 0.89 (95% confidence interval: 0.82–0.96). Empagliflozin (hazard ratio: 0.85) and dapagliflozin (hazard ratio: 0.85) were each associated with a significantly lower risk. These results suggest that sodium–glucose cotransporter 2 inhibitors…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 119,061 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.